Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
収録刊行物
-
- Journal of Thoracic Oncology
-
Journal of Thoracic Oncology 15 (2), 274-287, 2020-02
Elsevier BV